How to Value a Ukrainian Defense-Tech Company (2026)

The first thing that decides the method is whether you have recurring revenue. Ukrainian defense companies live in two different regimes, and confusing them is the most common mistake.

• With revenue.You are valued on a multiple of annual revenue. This is the “grown-up” regime: the number is anchored to real cash, not potential.
• Pre-revenue. No revenue yet, or only one-off sales — the base comes from a sector range for your stage (idea / prototype / early sales). Here investors price the technology, the team and the market, not the till.

Either way, that base is only a starting point. The mechanics that follow are the same: multiply the base by the factors that raise or lower risk for the investor.

Not all defense sectors are worth the same — and the main divide runs between software and hardware. Scalable software and AI earn higher, SaaS-adjacent multiples; hardware (drones, munitions, naval) is valued closer to revenue, like a manufacturer — lower margins, more capital intensity. These are the revenue multiples valuation starts from:

Pre-revenue companies use a sector base range instead of a multiple (from ~$0.5M for FPV and components up to ~$2.5–10M for AI and long-range systems), discounted for stage: an idea ≈ ×0.5, a prototype ≈ ×0.7. This is deliberately conservative — a pre-revenue valuation has a ceiling until a growth trajectory appears.

The base is half the story. Each attribute of the company then applies a multiplier: some raise the valuation, some lower it. They compound, and the combined effect is capped at ×0.5–×2.3, so no single answer swings the number too far. Here are the levers by impact:

Note the asymmetry: the three strongest upward levers are not “better technology” but codification, clean IP and combat proof. All three lower investor risk, and all three are in your control — before the first conversation about money.

Abstract multiples make sense on concrete cases. Both are illustrative, but computed on the same logic as the calculator.

Example A — FPV, prototype, pre-revenue

Product used at the front but sales are one-off; IP on the company without a patent; a single customer (an armed-forces unit); no codification. The FPV base at prototype stage is roughly $0.35–1.9M. Combat use adds ≈ +15%, but the single customer takes ≈ −7%. The indicative range lands around $0.8–1.5M, at a grant / angel round.

What lifts this company fastest: codification (+22%), a patent on the company (+18%) and a second or third customer. Each step is documents and contracts, not months of R&D.

Example B — growth-stage EW, with revenue

Annual revenue ≈ $10M; codified; three customer types including a foreign one; IP and code on the company with a patent; a cross-border structure; a management P&L and a data room; long-term contracts. EW is a hybrid, so the base is revenue × 3–6× ≈ $30–60M. Strong factors lift it → an indicative range around $52–61M, at a seed / growth round.

Some things don't just lower the number — they stop the deal before valuation even starts. Close these first.

1. 1Sanctions exposure. Any ties to russia/belarus or sanctioned persons — in ownership, the team or the supply chain — is ≈ −45% in the model and effectively disqualifying for Western capital. Check counterparties, not just yourself.
2. 2“Grey” IP.If the intellectual property and code sit with a founder personally or are unformalized, the deal won't assemble: an investor can't buy what the company doesn't legally own. That's ≈ −18% and the most common reason a valuation “doesn't hold.”
3. 3A single customer.All revenue from one buyer is concentration risk (≈ −7%) and a signal of fragility. Even if that single buyer is the Ministry of Defence, an investor reads it as a minus, not a plus — dependence on one customer, not “government = guaranteed.” A second and third channel — a foreign one especially — changes the company's profile.

The calculator gives a pre-NDA benchmark for a conversation. A defensible valuation for a real raise is different work: on your numbers, with sector comparables, for a specific investor. That is what gets defended to an investment committee and what sits in a term sheet.

A practical order of operations for most companies:

1. 1Compute your indicative range and see which factors are dragging you down.
2. 2Close the red lines (sanctions, IP on the company) and the cheapest upward levers (codification, a second customer, a data room).
3. 3Build a defensible valuation and a structure for Western capital — and go to the investor with a number that survives scrutiny.